![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1424447
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â ½ÃÀå : À¯Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, À¯Åë ä³Îº°, Áö¿ªº°Global Epinephrine Autoinjector Market, By Type, By End User, By Distribution Channel, By Geography |
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â ½ÃÀåÀº 2023³â 22¾ï ´Þ·¯¿¡¼ 2030³â¿¡´Â 39¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß CAGRÀº 8.6%ÀÔ´Ï´Ù.
¸®Æ÷Æ® ¹üÀ§ | ¸®Æ÷Æ® »ó¼¼ | ||
---|---|---|---|
±âÁسâ | 2022³â | 2023/2024³â ½ÃÀå ±Ô¸ð | 22¾ï ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2018-2021³â | ¿¹Ãø ±â°£ | 2023-2030 |
¿¹Ãø ±â°£ 2023³â/2024-2030³â/2031³â CAGR : | 8.60% | 2030/2031³â °¡Ä¡ ¿¹Ãø | 39¾ï 1,000¸¸ ´Þ·¯ |
¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â´Â ¾Æ³ªÇʶô½Ã½º¸¦ Æ÷ÇÔÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀÇ ÀÀ±Þ Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÑ ÀÏȸ¿ë ÀÚ±âÁÖ»ç±âÀÔ´Ï´Ù. ¾Æ³ªÇʶô½Ã½º´Â ƯÁ¤ À½½Ä, ÀǾàǰ, ¹ú·¹ ¹°¸² ¹× ±âŸ ¾Ë·¹¸£°Õ¿¡ ´ëÇÑ ±Ø½ÉÇÑ ¾Ë·¹¸£±â ¹ÝÀÀÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â »ý¸íÀ» À§ÇùÇÏ´Â »óÅÂÀÔ´Ï´Ù. ¾Æ³ªÇʶô½Ã½ºÀÇ Áõ»óÀ¸·Î´Â Ç÷¾Ð ÀúÇÏ, ÀÔ°ú ¸ñÀÇ ºÎÁ¾, ¹ßÁø, È£Èí°ï¶õ, ¼îÅ© µîÀÌ ÀÖ½À´Ï´Ù. ¾Æ³ªÇʶô½Ã½ºÀÇ °æ¿ì, ¿¡Çdz×ÇÁ¸°À» Àû½Ã¿¡ Åõ¿©ÇÏ¿© Áõ»óÀÇ ÁøÇàÀ» ¾ïÁ¦ÇØ¾ß ÇÕ´Ï´Ù. ¿¡Çdz×ÇÁ¸° ÀÚ°¡ ÁÖ»ç±â´Â ÁÖ»ç±â¿¡ ºñÇØ ¿¡Çdz×ÇÁ¸°À» ½Å¼ÓÇÏ°Ô ÀÚ°¡ Åõ¿©ÇÒ ¼ö ÀÖÀ¸¸ç, Àθí ÇÇÇØÀÇ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ¿¡Çdz×ÇÁ¸° ÀÚ°¡ÁÖ»ç±â ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ¾Æ³ªÇʶô½Ã½º À¯º´·ü Áõ°¡¿¡ µû¸¥ °ÍÀ¸·Î, FAAN(The Food Allergy and Anaphylaxis Network)ÀÇ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼¸¸ ¿¬°£ 5¸¸ °ÇÀÇ ¾Æ³ªÇʶô½Ã½º°¡ ¹ß»ýÇϸç, ±× Áß 150-200¸íÀÌ »ç¸ÁÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¹ß»ýÇϸç, ±× Áß 150-200°ÇÀÌ »ç¸Á¿¡ À̸£°í ÀÖ½À´Ï´Ù. ¾Ë·¹¸£±â¿Í °ü·ÃµÈ »ý¸íÀ» À§ÇùÇÏ´Â Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í °í±Þ ¿¡Çdz×ÇÁ¸° ÀÚ°¡ÁÖ»ç±âÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ÀåºñÀÇ ºñ¿ë°ú ½ÅÈï ±¹°¡ÀÇ ´ëü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ½ÃÀå ¼ºÀåÀ» Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù. Çâ»óµÈ »ç¿ë ÆíÀǼº, Á¤È®¼º ¹× ´õ ³ÐÀº Àû¿ë ¹üÀ§¸¦ °®Ãá Çõ½ÅÀûÀÎ ¿¡Çdz×ÇÁ¸° ÀÚ°¡ ÁÖ»ç±âÀÇ °³¹ßÀº ÇâÈÄ ¼ö³â°£ Á¦Á¶¾÷ü¿¡°Ô À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¡Çdz×ÇÁ¸° ÀÚ°¡ÁÖ»ç±â ½ÃÀåÀº ±â¼ú ¹ßÀü, ¾Æ³ªÇʶô½Ã½º¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, »ç¿ëÀÚ Ä£ÈÀû ¼³°è¿¡ ´ëÇÑ °ü½É Áõ°¡·Î ÀÎÇØ ÁÖ¸ñÇÒ ¸¸ÇÑ Æ®·»µå¸¦ ¸ñ°ÝÇϰí ÀÖ½À´Ï´Ù. ¹Ù´Ã ¾ø´Â ´ë¾È°ú ÈÆ·Ã¿ë µðÁöÅÐ °Ç° Ç÷§ÆûÀÌ °¢±¤À» ¹Þ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ÆíÀǼº°ú Á¢±Ù¼ºÀ» ³ôÀ̱â À§ÇØ ¹Ù´Ã ¾ø´Â ´ë¾ÈÀÌ °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÃÀåÀº Àü¿°º´ÀÇ ¿µÇâÀ» ¹Þ¾Æ ÁøÈÇÏ´Â »óȲ¿¡ ´ëÀÀÇϰí ÀÖÀ¸¸ç, ÀÇ·á ½Ã½ºÅÛ ¹× °ø±Þ¸Á¿¡ ´ëÇÑ ÀûÀÀ¼ºÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú Çõ½Å, ±â±â ±â´É °³¼±, Àü·«Àû Á¦ÈÞ°¡ ¿¡Çdz×ÇÁ¸° ÀÚ°¡ÁÖ»ç±â ½ÃÀåÀÇ ¿ªµ¿¼ºÀ» ´õ¿í °ÈÇϰí ÀÖÀ¸¸ç, ±Þº¯ÇÏ´Â ÀÇ·á ȯ°æ¿¡¼ À§Çè¿¡ óÇÑ °³Àΰú ÀÇ·á ¼ºñ½º ÇÁ·Î¹ÙÀÌ´õÀÇ ¿ä±¸¿¡ ºÎÀÀÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®Çϰí, 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¼³¸íÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ÇØ¼³Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À», ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±â¹ÝÇÏ¿© ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ±â¾÷Àº Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, Kaleo µîÀÔ´Ï´Ù.
º» ¸®Æ÷Æ®·ÎºÎÅÍ ¾òÀ» ¼ö ÀÖ´Â ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÏ¿© Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â ½ÃÀå ¸®Æ÷Æ®´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©¾÷ü, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¿¡°Ô ´ëÀÀÇϰí ÀÖ½À´Ï´Ù.
¼¼°èÀÇ ¿¡Çdz×ÇÁ¸° ÀÚ±âÁÖ»ç±â ½ÃÀåÀ» ºÐ¼®ÇÒ ¶§ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚ´Â ÀÇ»ç°áÁ¤ÀÌ ¿ëÀÌÇÏ°Ô µË´Ï´Ù.
Global epinephrine autoinjector market is expected to reach US$ 3.91 Bn by 2030, from US$ 2.20 Bn in 2023, exhibiting a CAGR of 8.6% during the forecast period.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2022 | Market Size in 2023/2024: | US$ 2.20 Bn |
Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
Forecast Period 2023/2024 to 2030/2031 CAGR: | 8.60% | 2030/2031 Value Projection: | US$ 3.91 Bn |
Epinephrine autoinjector is a single-use disposable automatic injection device that is intended for emergency treatment of allergic reactions including anaphylaxis. Anaphylaxis is a life-threatening condition that occur due to an extreme allergic reaction to certain foods, medicines, insects bites and other allergens. The symptoms of anaphylaxis include low blood pressure, swelling of the mouth or throat, rashes, breathing difficulty and shock. In case of anaphylaxis, epinephrine needs to be administered in a timely manner to curb the advancement of symptoms. Epinephrine autoinjectors enable rapid self-administration of epinephrine as compared to syringes, thereby, reducing the risk of casualty.
Global epinephrine autoinjector market growth is driven by rising prevalence of anaphylaxis worldwide. According to the data published by FAAN (The Food Allergy and Anaphylaxis Network), 50,000 cases of anaphylaxis occur annually in the U.S. alone, out of which 150-200 result in death. Increased awareness regarding life-threatening conditions associated with allergies along with availability of advanced epinephrine autoinjector devices are fueling the market demand. However, cost of these devices and preference for alternative treatment options in developing nations limits the market growth. Development of innovative epinephrine autoinjectors with improved usability, accuracy and larger coverage area is expected to present lucrative opportunities for manufacturers in the coming years.
The epinephrine autoinjector market is witnessing notable trends, driven by advancements in technology, increased awareness of anaphylaxis, and a growing emphasis on user-friendly designs. Needle-free alternatives and digital health platforms for training are gaining prominence, enhancing patient comfort and accessibility. The market is also responding to the evolving landscape influenced by the pandemic, necessitating adaptability in healthcare systems and supply chains. Continuous innovation, improved device features, and strategic collaborations are further shaping the dynamics of the epinephrine autoinjector market, aiming to address the needs of at-risk individuals and healthcare providers in a rapidly changing healthcare environment.
This report provides in-depth analysis of the global epinephrine autoinjector market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global epinephrine autoinjector market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Mylan, Teva Pharmaceutical, Impax Laboratories, Adamis Pharmaceuticals Corporation, Pfizer, ALK Abello, Lincoln Medical, Hospira, Sanofi, and Kaleo
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global epinephrine autoinjector market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global epinephrine autoinjector market